Novartis AG ADR
NYSE: NVS
$106.45
-$0.63 (-0.6%)
Closing Price on November 8, 2024
NVS Articles
The topic of acceptable costs versus acceptable results is one that may never have a final conclusion in which everyone agrees.
Published:
Last Updated:
Adamis Pharmaceuticals saw its shares shoot up early on Monday after the firm announced a partnership with a subsidiary of Novartis.
Published:
Last Updated:
It’s no surprise that it was only a matter of time before the usage and storage of big data and analytics would come to the health care sector, and many of the top companies are starting to apply...
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Agnico Eagle Mines, Ford, Marathon Petroleum, Roku, Spotify and Quest Diagnostics.
Published:
Last Updated:
Amgen shares saw a nice bump after the FDA on Thursday approved its preventive treatment of migraine in adults.
Published:
Last Updated:
These four top companies could be very attractive to large cap biotechs looking to add gene and cell therapy drugs to their portfolios.
Published:
Last Updated:
Swiss drug maker Novartis has agreed to acquire U.S.-based AveXis for $8.7 billion in cash. AveXis is developing a gene-therapy to treat an inherited disease to treat the leading cause of...
Published:
Last Updated:
Cancer immunotherapy approaches have attracted the attention of Big Pharma in the past. New technology from Stanford University probably will be no exception if Phase 1 results are positive.
Published:
Last Updated:
Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar market.
Published:
Last Updated:
Advanced Accelerator Applications shares made a run early on Monday after it came public that Novartis plans to buy the company.
Published:
Here are 13 featured spin-offs already underway and potential spin-offs that could be seen in 2017 and into 2018 that could radically change how Wall Street and Main Street evaluate companies ahead.
Published:
Last Updated:
According to Merrill Lynch, the health care sector should act as a good hedge against volatility. Even biotech was shown to offer growth at a reasonable price.
Published:
Last Updated:
Conatus Pharmaceuticals saw its shares make a handy gain on Friday after the firm announced an exclusive license agreement with Novartis.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include BHP Billiton, Capital One, Chemours, Constellation Brands, Novartis, Teradyne and Weyerhaeuser.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday include Chevron, Novartis, Randgold Resources, Urban Outfitters and Vodafone.
Published:
Last Updated: